- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00839969
Cystoscopy Plus Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding
A Randomized Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding.
Urethral dilatation is a commonly undertaken intervention for a variety of urinary complaints including overactive bladder symptoms. There is however very little evidence for its efficacy, and no randomized trial evidence. The aim of this study is to ascertain the effect of urethral dilatation on overactive bladder symptoms and on voiding parameters. The null hypothesis is that there will be no difference in symptoms or voiding parameters between the urethral dilatation and sham groups.
Eligible women will be assessed initially with a history and examination, a King's Health Questionnaire and Bristol Female Urinary Tract Symptoms (BFLUTS) questionnaire and pressure flow studies. They will be randomized to undergo either cystoscopy alone or cystoscopy and urethral dilatation. Patients will be blinded to the procedure undertaken and randomized using a series of opaque envelopes. Follow up will be at 6 weeks with repeat questionnaires and pressure flow studies. Subjective and objective outcomes will be compared between the two groups.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a randomised controlled trial. Objective outcomes will be evaluated at 6 weeks' post-operatively. Subjective outcomes will be evaluated at 6 weeks' and 6 months' post-operatively.
Study Population Entry to the study will be offered to all women with OAB symptoms with impaired voiding on cystometry (flow rate less than 15mls/sec with volume of 200mls voided and a normal or high detrusor pressure at maximum flow), who have failed to improve with 2 different anticholinergic medications. Subjects will be recruited from the Urogynaecology clinic at Medway Maritime Hospital. A power calculation was carried out which showed a minimum sample size of 30 (i.e. 15 in each arm) to be necessary to ensure an 80% power with a significance level of 0.05.
Pre-operative Assessment All patients will undergo an initial assessment consisting of a full urogynaecogical history and examination, BFLUTS questionnaire and Urgency Perception Scale, and pressure flow studies. As mentioned before, each patient will have been treated with anticholinergic medications prior to being offered this intervention.
Surgical Technique All procedures will be carried out under general anaesthesia. A dose of intravenous gentamicin will be given to each patient at induction. After emptying the bladder, saline cystoscopy will be carried out with a 30 degree cystoscope. The bladder mucosa will be systematically inspected for any abnormalities and the bladder filled either until the sphincter mechanism is overcome or to 1000mls. The bladder is emptied again and a second fill undertaken. The bladder mucosa is inspected for petechial haemorrhages, erythema and other signs of chronic cystitis on the second fill.
In subjects randomised to undergo urethral dilatation, this will be undertaken using Hagar dilators. There is no evidence in the literature regarding normal urethral calibre in women. Therefore, the urethra will be dilated to a maximum of 10 Hagar as per our unit's protocol. Women will be discharged on the same day, if they pass urine adequately.
Post-operative Assessment Subjects will be seen in the Urogynaecology clinic at 6 weeks' post-operatively and assessed with a BFLUTS questionnaire, UPS and repeat pressure flow studies. Each patient will be assessed subjectively at 6 months' post-operatively using the symptom questionnaires.
Significance testing will be used to compare symptom scores and pressure flow parameters between each group pre- and post-operatively.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kent
-
Gillingham, Kent, United Kingdom, ME7 5NY
- Recruiting
- Medway Maritime Hospital
-
Principal Investigator:
- Jonathan Duckett, FRCOG
-
Sub-Investigator:
- Maya Basu, MBBS, BSc(Hons)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- OAB symptoms (based on relevant domains of BFLUTS questionnaire and Urgency Perception Scale) which have not improved with 2 anticholinergic treatments.
- Maximum flow rate of less than 15 ml/s on a volume voided of 200mls or more, with a normal or high detrusor pressure at maximum flow on pressure flow studies
- Patients must be able to give informed consent for the study
Exclusion Criteria:
- Presence of concurrent urodynamic stress incontinence
- Patient unfit or unwilling to undergo a general anaesthetic
- Patients with bladder pathology or haematuria of unknown origin
- Patients with neurological disorders (as these may affect voiding)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
SHAM_COMPARATOR: Cystoscopy alone
Women in this arm will undergo saline cystoscopy under general anaesthesia only.
|
Saline cystoscopy under general anaesthesia
|
ACTIVE_COMPARATOR: Cystoscopy and urethral dilatation
Women in this group will undergo cystoscopy and urethral dilatation under general anaesthesia
|
Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in pressure flow parameters (voided volume, maximum flow rate, acceleration of flow rate and detrusor pressure at maximum flow) at 6 weeks' post-operatively.
Time Frame: 6 weeks
|
6 weeks
|
Change in symptoms as measured by the BFLUTS questionnaire and Urgency Perception Scale at 6 weeks' and 6 months' post-operatively.
Time Frame: 6 weeks and 6 months
|
6 weeks and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in quality of life status as determined by change in King's Health Questionnaire scoring at 6 weeks and 6 months' post-operatively.
Time Frame: 6 weeks and 6 months
|
6 weeks and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jonathan Duckett, FRCOG, Medway NHS Trust
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08/H1101/97
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder Syndrome
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Taipei Veterans General Hospital, TaiwanRecruitingOveractive Bladder SyndromeTaiwan
-
Buddhist Tzu Chi General HospitalUnknownOveractive Bladder SyndromeTaiwan
-
Radboud University Medical CenterWithdrawn
-
PfizerCompleted
-
PfizerCompletedOveractive Bladder SyndromeGermany
-
Walter Reed National Military Medical CenterRecruitingOveractive Bladder SyndromeUnited States
-
University Hospital, GhentAstellas Pharma Inc; MedtronicCompleted
-
University Hospital, GhentTerminatedOveractive Bladder SyndromeBelgium
-
Chung Shan Medical UniversityUnknownOveractive Bladder SyndromeTaiwan
Clinical Trials on Cystoscopy
-
Western University, CanadaCompletedBladder Cancer | Hematuria | Bladder DiseaseCanada
-
University of Wisconsin, MadisonCompletedUrination Disorders | Hematuria | Recurrent Urinary Tract Infection | Voiding DysfunctionUnited States
-
Boston Scientific CorporationCompletedBenign Prostatic Hyperplasia | Lower Urinary Tract SymptomUnited States
-
Medway NHS Foundation TrustCompletedUrinary Incontinence, UrgeUnited Kingdom
-
Medway NHS Foundation TrustWithdrawnOveractive Bladder | Urinary Incontinence | Voiding Dysfunction
-
University of OklahomaCompleted
-
Mansoura UniversityUnknownPain, Postoperative | Bladder Cancer | Flexible Cystoscopy | Non-muscle Invasive Bladder Cancer (NMIBC)Egypt
-
Nellie Medical, LLCUnknownBladder Infections and Inflammations
-
AdventHealthCompleted